Charles Schwab’s Bristol-Myers Squibb BMY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $3.71B | Sell |
61,115,373
-10,207,019
| -14% | -$595M | 0.57% | 38 |
|
|
2025
Q4 | $3.85B | Sell |
71,322,392
-1,717,931
| -2% | -$82.6M | 0.6% | 34 |
|
|
2025
Q3 | $3.29B | Buy |
73,040,323
+2,237,643
| +3% | +$105M | 0.53% | 36 |
|
|
2025
Q2 | $3.28B | Buy |
70,802,680
+10,195,775
| +17% | +$500M | 0.57% | 35 |
|
|
2025
Q1 | $3.7B | Buy |
60,606,905
+306,430
| +0.5% | +$17.9M | 0.69% | 34 |
|
|
2024
Q4 | $3.41B | Sell |
60,300,475
-729,928
| -1% | -$40.8M | 0.63% | 33 |
|
|
2024
Q3 | $3.16B | Buy |
61,030,403
+1,968,729
| +3% | +$92.4M | 0.6% | 34 |
|
|
2024
Q2 | $2.45B | Buy |
59,061,674
+5,345,708
| +10% | +$239M | 0.47% | 43 |
|
|
2024
Q1 | $2.91B | Buy |
53,715,966
+42,354,249
| +373% | +$2.16B | 0.67% | 28 |
|
|
2023
Q4 | $583M | Buy |
11,361,717
+134,815
| +1% | +$7.08M | 0.15% | 119 |
|
|
2023
Q3 | $652M | Buy |
11,226,902
+1,128
| +0% | +$69.1K | 0.19% | 95 |
|
|
2023
Q2 | $718M | Sell |
11,225,774
-127,692
| -1% | -$8.56M | 0.21% | 83 |
|
|
2023
Q1 | $787M | Buy |
11,353,466
+146,367
| +1% | +$10.3M | 0.24% | 78 |
|
|
2022
Q4 | $806M | Buy |
11,207,099
+70,887
| +0.6% | +$5.34M | 0.26% | 73 |
|
|
2022
Q3 | $792M | Buy |
11,136,212
+311,466
| +3% | +$22.6M | 0.28% | 62 |
|
|
2022
Q2 | $834M | Sell |
10,824,746
-180,727
| -2% | -$13.8M | 0.29% | 65 |
|
|
2022
Q1 | $804M | Buy |
11,005,473
+197,000
| +2% | +$13.2M | 0.24% | 78 |
|
|
2021
Q4 | $674M | Buy |
10,808,473
+129,007
| +1% | +$7.57M | 0.2% | 93 |
|
|
2021
Q3 | $632M | Buy |
10,679,466
+326,265
| +3% | +$21.5M | 0.21% | 88 |
|
|
2021
Q2 | $692M | Buy |
10,353,201
+204,683
| +2% | +$13.3M | 0.23% | 78 |
|
|
2021
Q1 | $641M | Sell |
10,148,518
-372,144
| -4% | -$23.2M | 0.23% | 81 |
|
|
2020
Q4 | $653M | Buy |
10,520,662
+19,751
| +0.2% | +$1.21M | 0.26% | 74 |
|
|
2020
Q3 | $633M | Sell |
10,500,911
-661,878
| -6% | -$39.8M | 0.29% | 69 |
|
|
2020
Q2 | $656M | Sell |
11,162,789
-8,458,990
| -43% | -$506M | 0.32% | 58 |
|
|
2020
Q1 | $1.09B | Sell |
19,621,779
-40,694
| -0.2% | -$2.49M | 0.64% | 27 |
|
|
2019
Q4 | $1.26B | Buy |
19,662,473
+5,861,939
| +42% | +$336M | 0.68% | 22 |
|
|
2019
Q3 | $700M | Buy |
13,800,534
+371,981
| +3% | +$17.5M | 0.41% | 40 |
|
|
2019
Q2 | $609M | Buy |
13,428,553
+593,222
| +5% | +$27.6M | 0.37% | 47 |
|
|
2019
Q1 | $612M | Buy |
12,835,331
+6,027,123
| +89% | +$300M | 0.39% | 39 |
|
|
2018
Q4 | $354M | Buy |
6,808,208
+273,010
| +4% | +$14.7M | 0.27% | 68 |
|
|
2018
Q3 | $406M | Buy |
6,535,198
+251,993
| +4% | +$15M | 0.27% | 66 |
|
|
2018
Q2 | $348M | Buy |
6,283,205
+172,417
| +3% | +$9.31M | 0.25% | 70 |
|
|
2018
Q1 | $387M | Buy |
6,110,788
+229,151
| +4% | +$14.7M | 0.3% | 56 |
|
|
2017
Q4 | $360M | Buy |
5,881,637
+263,197
| +5% | +$16.5M | 0.29% | 56 |
|
|
2017
Q3 | $358M | Buy |
5,618,440
+216,099
| +4% | +$12.6M | 0.31% | 50 |
|
|
2017
Q2 | $301M | Buy |
5,402,341
+270,982
| +5% | +$14.7M | 0.28% | 55 |
|
|
2017
Q1 | $279M | Buy |
5,131,359
+227,978
| +5% | +$12.5M | 0.28% | 57 |
|
|
2016
Q4 | $287M | Buy |
4,903,381
+193,619
| +4% | +$10.6M | 0.31% | 52 |
|
|
2016
Q3 | $254M | Buy |
4,709,762
+90,897
| +2% | +$5.84M | 0.3% | 52 |
|
|
2016
Q2 | $340M | Buy |
4,618,865
+131,618
| +3% | +$9.3M | 0.42% | 41 |
|
|
2016
Q1 | $287M | Buy |
4,487,247
+107,148
| +2% | +$6.76M | 0.38% | 46 |
|
|
2015
Q4 | $301M | Buy |
4,380,099
+149,556
| +4% | +$9.88M | 0.41% | 45 |
|
|
2015
Q3 | $250M | Sell |
4,230,543
-36,528
| -0.9% | -$2.32M | 0.37% | 49 |
|
|
2015
Q2 | $284M | Buy |
4,267,071
+66,201
| +2% | +$4.36M | 0.39% | 50 |
|
|
2015
Q1 | $271M | Buy |
4,200,870
+187,738
| +5% | +$11.8M | 0.38% | 50 |
|
|
2014
Q4 | $237M | Buy |
4,013,132
+88,722
| +2% | +$5M | 0.36% | 51 |
|
|
2014
Q3 | $201M | Sell |
3,924,410
-307,636
| -7% | -$15.4M | 0.33% | 55 |
|
|
2014
Q2 | $205M | Buy |
4,232,046
+245,281
| +6% | +$12.1M | 0.35% | 53 |
|
|
2014
Q1 | $207M | Sell |
3,986,765
-638,012
| -14% | -$33.9M | 0.37% | 49 |
|
|
2013
Q4 | $246M | Buy |
4,624,777
+247,182
| +6% | +$12.6M | 0.47% | 40 |
|
|
2013
Q3 | $207M | Buy |
4,377,595
+365,855
| +9% | +$16.1M | 0.42% | 41 |
|
|
2013
Q2 | $180M | Buy |
+4,011,740
| New | +$174M | 0.4% | 40 |
|
Other funds holding BMY
VCM
VPM
Charles Schwab's BMY Position: Q1 2026 in Review
Charles Schwab reduced its Bristol-Myers Squibb (BMY) stake by 14% in Q1 2026, selling an estimated $595M and leaving 61,115,373 shares worth $3.71B. The position accounts for 0.57% of the portfolio, ranked #38.
Charles Schwab first reported a position in BMY in Q2 2013 and has held it in 52 quarters since. The position peaked at $3.85B in Q4 2025. 2,519 funds tracked by Wall St. Rank hold BMY as of Q1 2026.
- Charles Schwab held 61,115,373 shares of Bristol-Myers Squibb worth $3.71B as of Q1 2026.
- Charles Schwab sold 10,207,019 Bristol-Myers Squibb shares in Q1 2026, an estimated $595M.
- Bristol-Myers Squibb made up 0.57% of Charles Schwab's portfolio in Q1 2026, its #38 holding.
- Charles Schwab first reported a position in Bristol-Myers Squibb in Q2 2013 and has held it in 52 quarters since.
- Charles Schwab's Bristol-Myers Squibb position peaked at $3.85B in Q4 2025.
- 2,519 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.
Based on Charles Schwab's 13F filing for Q1 2026, filed 15 May 2026.